Nanobiotix SA

NANO

Company Profile

  • Business description

    Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

  • Contact

    60 Rue de Wattignies
    Paris75012
    FRA

    T: +33 140260470

    https://www.nanobiotix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    108

Stocks News & Analysis

stocks

ResMed earnings: Solid showing from ASX healthcare winner

Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
stocks

Is this the $80 billion elephant Warren Buffett has been waiting for?

Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.
stocks

Tesla: Board announces new pay package for CEO Elon Musk

A key provision of the new award is that Musk must remain in a senior leadership position at Tesla.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,028.80106.801.20%
CAC 407,654.1622.150.29%
DAX 4023,968.52210.830.89%
Dow JONES (US)44,173.64585.061.34%
FTSE 1009,168.2339.930.44%
HKSE24,902.53169.080.68%
NASDAQ21,053.58403.451.95%
Nikkei 22540,549.54258.840.64%
NZX 50 Index12,877.04193.001.52%
S&P 5006,329.940.000.00%
S&P/ASX 2008,770.40106.701.23%
SSE Composite Index3,617.6034.290.96%

Market Movers